Editorial Board

Editor-in-Chief

Al Benson, MD

Northwestern University Chicago, IL

Sanjiv Agarwala, MD

Temple University School of Medicine Philadelphia, PA St. Luke’s Cancer Center Bethlehem, PA
Breast Cancer

Minetta Liu, MD

Georgetown University Hospital Washington, DC

Edith Perez, MD

Mayo Clinic Jacksonville, FL

Hope S. Rugo, MD

University of California, San Francisco San Francisco, CA

Lawrence N. Shulman, MD

Dana-Farber Cancer Institute Boston, MA
Biostatistics

Gregory D. Ayers, MS

Vanderbilt University School of Medicine Nashville, Tennessee
Drug Development

Igor Puzanov, MD

Vanderbilt University Vanderbilt-Ingram Cancer Center Nashville, TN
Gastrointestinal Cancer

Katie Kelley, MD

UCSF School of Medicine San Francisco, CA

Eunice Kwak, MD

Massachusetts General Hospital Cancer Center Harvard Medical School Boston, MA

Darren Sigal, MD

Scripps Clinic Medical Group San Diego, CA
Government Affairs

Danielle Scelfo, MHSA

Genomic Health Redwood City, CA
Hematologic Malignancies

Gautam Borthakur, MD

MD Anderson Cancer Center Houston, Texas

Leif Bergsagel, MD

Mayo Clinic Scottsdale, Arizona

Beth Faiman, RN, MSN, APRN, BC, AOCN

Cleveland Clinic Taussig Cancer Center Cleveland, Ohio

Steven D. Gore, MD

The Johns Hopkins University School of Medicine Baltimore, Maryland

Nikhil C. Munshi, MD

Dana-Farber Cancer Institute Boston, Massachusetts

Steven T. Rosen, MD, FACP

Northwestern University Chicago, IL

Lee Schwartzberg, MD

The West Clinic Memphis, Tennessee

Moshe Talpaz, MD

University of Michigan Medical Center Ann Arbor, Michigan

Anas Younes,MD

MD Anderson Cancer Center Houston, Texas
Lung Cancer

Lyudmila Bazhenova, MD

University of California, San Diego San Diego, CA

Gilberto Castro, MD

Instituto do Câncer do Estado de São Paulo São Paulo, Brazil

Vincent A. Miller, MD

SVP Clinical Development, Foundation Medicine Consultant, Thoracic Oncology Memorial Sloan-Kettering Cancer Center

Rafael Rosell, MD, PhD

Catalan Institute of Oncology Barcelona, Spain

David Spigel, MD

Sarah Cannon Research Institute Nashiville, Tennessee
Melanoma

Sanjiv S. Agarwala, MD

St. Luke’s Hospital Bethlehem, PA

Madeleine Duvic, MD

The University of Texas MD Anderson Cancer Center Houston, TX

Howard L. Kaufman, MD, FACS

Rush University Chicago, IL

Kim Margolin, MD

University of Washington Fred Hutchinson Cancer Research Center Seattle, WA

Steven O’Day, MD

John Wayne Cancer Institute Santa Monica, CA

Doug Schwartzentruber, MD

Indiana University Simon Cancer Center Indianapolis, IN
Pathology

Mark S. Boguski, MD, PhD Harvard Medical School Boston, MA

David L. Rimm, MD, PhD

Yale Pathology Tissue Services Yale University School of Medicine New Haven, CT

Jaime Shutter, MD

South Beach Medical Consultants, LLC Miami Beach, Florida
Pharmacology

Gene Morse, PharmD

University at Buffalo Buffalo, New York
Predictive Modeling

Michael Kattan, PhD

Case Western Reserve University Cleveland, OH
Prostate Cancer

Oliver Sartor, MD

Tulane University New Orleans, LA
Regulatory Policy

Sheila D. Walcoff, JD

Goldbug Strategies, LLC Rockville, Maryland
Science and Technology

Tony Albino, PhD

Executive Vice-President,
Science & Technology
Signal Genetics LLC
New York, NY

Kenneth Bloom, MD

Clarient Inc.
Aliso Viejo, CA

Stephen Gately, MD

TGen Drug Development (TD2)
Scottsdate, Arizona

K. Peter Hirth, PhD

Plexxikon, Inc.
Berkeley, California

Afsaneh Motamed-Khorasani, PhD

Radient Pharmaceutical
Tustin, California

David A. Proia, PhD

Synta Pharmaceuticals
Lexington, Massachusetts

John Shaughnessy, PhD

Signal Genetics, LLC
New York, NewYork